Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Cha, Yong-Mei
Asirvatham, Samuel J.
Abrégé
This document relates to methods and materials for providing stimulation or ablation to the stellate ganglion. For example, this document relates to methods and devices for providing stimulation or ablation to the stellate ganglion to modify blood pressure.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
A61N 1/365 - Stimulateurs cardiaques commandés par un paramètre physiologique, p. ex. par le potentiel cardiaque
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Forte, Antonio J.
Kuehn, Stephen T.
Lange, Jonathon W.
Bruhnke, Russell E.
Corner, Stephen M.
Angeli, John M.
Robinson, Shawn P.
King, Tyler S.
Klebel, Brandon J.
Stangler, Luke A.
Abrégé
Devices, methods, and kits can be designed and used for tissue removal. In some examples, a tissue removal device includes a handle assembly, a rechargeable battery, a motor system with a reciprocating motor shaft electrically coupled to the rechargeable battery, and a head assembly releasably coupled to the handle assembly. The head assembly can include a blade. The blade can be configured for linear movement that is transverse to a longitudinal axis of the handle assembly and responsive to a movement of the reciprocating motor shaft.
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
3.
DEVICES AND METHODS FOR TRANSVASCULAR DRAINAGE OF FLUIDS IN AN INTRACRANIAL EXTRAVASCULAR SPACE
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Savastano, Luis E.
Liu, Yang
Abrégé
Devices and methods are described for accessing an intracranial extravascular space of a patient. For example, this disclosure describes devices and methods for drainage of a subdural hematoma disposed within an intracranial extravascular space of a patient.
A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Lennon, Vanda A.
Pittock, Sean J.
Hinson, Shannon
Abrégé
The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
5.
MULTISCALE BRAIN ELECTRODE DEVICES AND METHODS FOR USING THE MULTISCALE BRAIN ELECTRODES
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Brinkmann, Benjamin H.
Stead, Squire Matthew
Worrell, Gregory A.
Abrégé
Multiscale brain electrodes can be used for spatiotemporal mapping, probing, and therapeutic modulation of the human brain. The applications for such functional mapping and electrical stimulation modulation span, for example, neurological and psychiatric diseases, and brain rehabilitation.
A61B 5/291 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/053 - Mesure de l'impédance ou de la conductivité électrique d'une partie du corps
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Lifson, Mark A.
Vidal, David E.
Sehgal, Ajai
Eggebraaten, Thomas J.
Abrégé
A framework for software development in regulated industries enables users from different domains to collaborate effectively and create documentation and/or objective evidence for development activities using their own language and expertise. The framework provides guidance for meeting regulatory expectations, if necessary, and can also help teams quickly identify redundant workstreams, share work across teams, and increase communication between disparate groups.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Lake, Douglas
Pfeffer, Kirsten
Ho, Thai
Abrégé
The present disclosure provides an anti-galectin-1 monoclonal antibody and methods of its use to detect intracellular or cell surface galectin-1. The disclosure also provides methods for using the anti-galectin-1 antibody to detect β-galactoside on a cell surface.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/532 - Production de composés immunochimiques marqués
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
8.
ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Sangaralingham, Sasantha J.
Burnett, Jr., John C.
Malany, Siobhan
Peddibhotla, Satyamaheshwar
Abrégé
In some embodiments, the present disclosure provides a compound of Formula (I):
In some embodiments, the present disclosure provides a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein X1, X2, R3-R8, and n are as disclosed herein. In some embodiments, the present disclosure provides a pharmaceutical composition comprising any of the compounds as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, the present disclosure provides a method of modulating particulate guanylyl cyclase receptor A (pGC-A) in a cell, the method comprising contacting the cell with an effective amount of any one of the compounds as described herein, or a pharmaceutically acceptable salt thereof.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
9.
METHODS AND SYSTEMS FOR PREDICTING RESPONSE TO PD-1 AXIS DIRECTED THERAPEUTICS IN COLORECTAL TUMORS WITH DEFICIENT MISMATCH REPAIR
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Ahanonu, Eze O.
Mcmahon, Sara Marie
Shanmugam, Kandavel
Sinicrope, Frank A.
Williams, Crystal Sue
Yan, Dongyao
Zhang, Wenjun
Abrégé
Scoring functions for predicting response of a dMMR and/or MSI-H colorectal tumor to a PD-1 axis-directed therapy are disclosed, as well as methods and systems for evaluating tissue samples for the presence of feature metrics useful in computing such scoring functions. The scoring functions integrate one or more spatial relationships between cell types into a numerical indication of the likelihood that the tumor will respond to the PD-1 axis-directed therapy. Based on the output of the scoring function, a subject may then be selected to receive a PD-1 axis-directed therapy (if the scoring function indicates a sufficient likelihood of positive response) or an alternative therapy (if the scoring function indicates an insufficient likelihood of positive response).
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Ikezu, Tsuneya
You, Yang
Zhang, Zhengrong
Abrégé
Methods and materials for identifying and using neuron-specific extracellular vesicles are provided herein. For example, provided herein are methods and materials for identifying neuron-specific extracellular vesicles and assessing the presence and/or amount of disease biomarkers associated with the identified extracellular vesicles.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
11.
RADIOGRAPHIC IMAGE GENERATION USING GENERATIVE ARTIFICIAL INTELLIGENCE MODELS
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Wyles, Cody C.
Khosravi, Bardia
Rouzrokh, Pouria
Erickson, Bradley J.
Taunton, Michael J.
Abrégé
Generative artificial intelligence (AI) models are used to generate synthetic images from one or more radiographic images of a subject. As one example, a radiographic image of a subject in a first view can be converted to a view-corrected radiographic image of the subject in a second view. As another example, two or more radiographic images of a subject can be used to generate a three-dimensional (3D) anatomical model, such as a 3D model of bony structures in the subject. To ensure consistency of the synthetic images with the input radiographic images, a radiographic fingerprint is generated from the input images and used to condition the generative models. The radiographic fingerprint may be an embedding vector that encodes unique anatomical features depicting in the input images.
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
G06T 17/00 - Modélisation tridimensionnelle [3D] pour infographie
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Systematization of data in computer databases; Updating and maintenance of data in computer databases; Data processing services; Database management Platform as a service (PAAS) featuring computer software platforms for analysis of medical patient data; Providing online non-downloadable software programs for use in analyzing and compiling clinical health care data; Providing online non-downloadable software programs for use in analyzing and compiling data relating to medical conditions, treatments, and therapies; Scientific research in the nature of conducting clinical trials for others in the field of health care, namely relating to development of digital biomarkers or endpoints to support improved patient care; Development, updating and maintenance of software and database systems; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for Early Disease Detection and Predictive Insights, such as pre-screening patients for clinical trials; Providing an on-line searchable database in the field of biopharmaceuticals and pharmaceuticals for scientific research purposes; Medical research services; Pharmaceutical research services; Research and development of medicines; Pharmaceutical drug development services; Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; Research and development services in the field of medical preparations; Scientific study and research in the field of medicine, the prevention, treatment and management of illness, health care delivery; Platform as a service (PAAS) featuring cloud computing tools for development of statistical models, data analytics, machine learning, and artificial intelligence models in the field of health care; Providing access to an online non-downloadable data network program that synthesizes and analyzes health care data; Remote monitoring of medical data for research purposes; Providing an online searchable database featuring de-identified clinical patient data; Providing an online searchable database containing information for use by data scientists in the fields of health diseases and disorders; Data compiling and analyzing health data in the field of health care; Updating and maintenance of database systems, which refers collectively to the database model, database management system and database content; Consulting services in the field of medical device development and design; Medical device development, namely, product development services for others in the field of medical devices; Biotechnology consulting; Product design and development in the field of medical devices Remote monitoring of medical data for medical diagnosis and treatment; Remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; Health care services, namely, providing a database in the field of Early Disease Detection information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Medical diagnostic services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the web site that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; Medical testing for diagnostic or treatment purposes; Medical diagnostic, testing, monitoring and reporting services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; Providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Systematization of data in computer databases; Updating and maintenance of data in computer databases; Data processing services; Database management Platform as a service (PAAS) featuring computer software platforms for analysis of medical patient data; Providing online non-downloadable software programs for use in analyzing and compiling clinical health care data; Providing online non-downloadable software programs for use in analyzing and compiling data relating to medical conditions, treatments, and therapies; Scientific research in the nature of conducting clinical trials for others in the field of health care, namely relating to development of digital biomarkers or endpoints to support improved patient care; Development, updating and maintenance of software and database systems; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for Early Disease Detection and Predictive Insights, such as pre-screening patients for clinical trials; Providing an on-line searchable database in the field of biopharmaceuticals and pharmaceuticals for scientific research purposes; Medical research services; Pharmaceutical research services; Research and development of medicines; Pharmaceutical drug development services; Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; Research and development services in the field of medical preparations; Scientific study and research in the field of medicine, the prevention, treatment and management of illness, health care delivery; Platform as a service (PAAS) featuring cloud computing tools for development of statistical models, data analytics, machine learning, and artificial intelligence models in the field of health care; Providing access to an online non-downloadable data network program that synthesizes and analyzes health care data; Remote monitoring of medical data for research purposes; Providing an online searchable database featuring de-identified clinical patient data; Providing an online searchable database containing information for use by data scientists in the fields of health diseases and disorders; Data compiling and analyzing health data in the field of health care; Updating and maintenance of database systems, which refers collectively to the database model, database management system and database content; Consulting services in the field of medical device development and design; Medical device development, namely, product development services for others in the field of medical devices; Biotechnology consulting; Product design and development in the field of medical devices Remote monitoring of medical data for medical diagnosis and treatment; Remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; Health care services, namely, providing a database in the field of Early Disease Detection information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Medical diagnostic services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the web site that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; Medical testing for diagnostic or treatment purposes; Medical diagnostic, testing, monitoring and reporting services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; Providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms
14.
MAGNETIC SURGICAL CLIP, AND ASSOCIATED SYSTEM AND METHOD FOR MANIPULATION OF TISSUE
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Marvi, Hamidreza
Jue, Terry
Askari, Tabsheer
Abrégé
A surgical clip with one or more premagnetized elements is configured to be delivered with an endoscope or similar device, and a system and method for manipulating tissue during a surgical procedure using such a surgical clip, are provided. At least one magnetic field source arranged external to an animal body is moved using at least one robotic actuator, and a magnetic field generated thereby is used to alter position of one or more surgical clips affixed to tissue. A surgical clip includes a tubular body structure, a grasping element, and internal elements within the body structure, wherein at least portions of one or more of the body structure and the internal elements comprise a premagnetized material configured to cooperate with a magnetic end effector external to the animal body to permit manipulation of tissue.
A61B 17/10 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour poser ou retirer les clamps pour blessuresChargeurs de clamps pour blessures
A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
15.
SURGICAL CLIP WITH TETHERED MAGNETIC ELEMENT, AND ASSOCIATED SYSTEM AND METHOD FOR MANIPULATION OF TISSUE
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Marvi, Hamidreza
Jue, Terry
Askari, Tabsheer
Abrégé
A surgical clip with a tethered magnetic element configured to be delivered with an endoscope or similar device, and a system and method for manipulating tissue during a surgical procedure using such a surgical clip, are provided. At least one magnetic field source arranged external to an animal body is moved using at least one robotic actuator, and a magnetic field generated thereby is used to alter position of one or more surgical clips affixed to tissue. A surgical clip includes a tubular body structure, a grasping element, and internal elements within the body structure. While the surgical clip grasps tissue, the tethered magnetic element is configured to cooperate with a magnetic end effector external to the animal body for manipulation of tissue.
A61B 17/10 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour poser ou retirer les clamps pour blessuresChargeurs de clamps pour blessures
A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Mehner, Christine
Turnbull, Marion T.
Abrégé
Intramedullary nails can be used for the treatment of a bone fracture. In some embodiments, such intramedullary nails can include an elongate shaft having a longitudinal axis, a distal nail component, and a proximal nail component. In some embodiments, the intramedullary nails include a first rotatable shaft and a second rotatable shaft. In some embodiments, the intramedullary nails include a handle coupled to the first and second rotatable shafts.
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (USA)
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Ardecky, Robert J.
Zou, Jiwen
Ganji, Santhi Reddy
Abelman, Matthew
Vuong, Krystine N.
Masyuk, Tetyana V.
Larusso, Nicholas F.
Masyuk, Anatoliy
Jackson, Michael R.
Olson, Steven H.
Sergienko, Eduard
Holleran, John
Ma, Chen-Ting
Chung, Thomas D.Y.
Pinkerton, Anthony B.
Abrégé
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof that are useful for treating a disease associated with TGR5.
C07D 235/18 - BenzimidazolesBenzimidazoles hydrogénés avec des radicaux aryle liés directement en position 2
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/423 - Oxazoles condensés avec des carbocycles
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
C07D 277/66 - Benzothiazoles avec uniquement des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués liés en position 2 avec des cycles ou des systèmes cycliques aromatiques liés directement en position 2
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07C 331/28 - Isothiocyanates ayant des groupes isothiocyanate liés à des atomes de carbone de cycles aromatiques à six chaînons
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
G01N 23/00 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Jiang, Haifei
Russell, Stephen James
Abrégé
This document relates to methods and materials involved in treating a mammal (e.g., a human) having cancer and/or an infectious disease. For example, this document provides recombinant human cytomegalovirus (hCMV) vectors that include (e.g., are designed to include) nucleic acid encoding a viral gene transfer vector genome (e.g., a heterologous viral gene transfer vector genome) and one or more nucleic acids encoding a packaging polypeptide such that a cell of a mammal that is infected with the hCMV vector can produce and release the viral vector (e.g., an infectious lentiviral vector) which can then infect cells (e.g., immune cells) in vivo and can, optionally, drive expression of an exogenous polypeptide (e.g., a therapeutic polypeptide or an antigen receptor such as a chimeric antigen receptor (CAR)) in the infected immune cells within a mammal (e.g., a human) to induce an immune response within the mammal are provided.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Urban, Matthew W.
Lee, Hyungkyi
Abrégé
Systems and methods for measuring material properties of a medium are described. Operations include receiving data from a receiver such as an ultrasound receiver, the data including a representation of particle motion over time in a spatial dimension, generating a time delay map from the data, wherein a first axis of the time delay map corresponds to each of a plurality of points in the spatial dimension as a measurement point and wherein a second axis of the time delay map corresponds to each of the plurality of points in the first spatial dimension as a reference point; determining a time delay surface based on a maximum value of a cross-correlation function for the time delay map, wherein the cross-correlation function is configured to determine a relationship between a plurality of measurement points and a plurality of reference points, and determining a wave velocity based on the time delay surface.
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
21.
DEVICES AND METHODS FOR CREATING OR AUGMENTING GASTRIC FLAP VALVES
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Abu Dayyeh, Barham, K.
Abrégé
This document provides devices and methods for prosthetic flap valve system, comprising an elongation member having a first end and a second end, a first anchor member coupled to the first end of the elongation member and configured to couple the first end of the elongation member to the gastric wall of a subject, a second anchor member coupled to the second end of the elongation member and configured to couple the second end of the elongation member to a flap valve, wherein, the elongation member is configured to bias the flap valve to a closed position, and the closed position of the flap valve provides a separation between the esophagus and the stomach.
A61B 17/122 - Clamps ou pinces, p. ex. pour le cordon ombilical
A61B 17/128 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical pour appliquer ou enlever les clamps ou les pinces
A61F 2/04 - Éléments ou organes creux ou tubulaires, p. ex. vessies, trachées, bronches ou voies biliaires
A61F 5/00 - Procédés ou dispositifs d'orthopédie pour le traitement non chirurgical d'os ou articulationsDispositifs pour donner des soins
A61B 17/04 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour la suture des plaiesSupports ou emballages pour aiguilles ou matériaux de suture
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Hsieh, Scott S.
Abrégé
X-ray detector efficiency and/or resolution are improved by using x-ray fluorescent materials in the x-ray detector design. The x-ray fluorescent components capture incident x-rays and emit fluorescent x-rays that are detected by adjacent x-ray detector elements. A component of the x-ray detector may be made x-ray fluorescent by incorporating a high-Z element-containing material into the x-ray detector component design. The x-ray fluorescent detector component may be an interpixel reflecting septa, a backing layer, and/or an interdetector reflector for multilayer detectors.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Abu Dayyeh, Barham K.
Tri, Jason A.
Asirvatham, Samuel J.
Mullon, John J.
Kern, Ryan M.
Abrégé
Devices, systems, and methods described in this disclosure can be used to deliver electroporation and adjunct therapies to treat anastomotic leaks and the resulting abscess cavities around the GI tract, within the thoracic cavity, and elsewhere within the human body. The thermal or non-thermal electroporation therapy can be delivered using the devices, systems, and methods described herein. In some embodiments, the electroporation energy is delivered to achieve sterilization and promote healing of spaces such as abscess cavities.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Lake, Douglas
Ho, Thai
Koelbel, Calvin
Abrégé
Provided are antibodies specific for the long isoform of QSOX1 and methods of using these antibodies to detect and measure the levels of the presence of the long and short isoforms of QSOX1 in a sample.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Tizhoosh, Hamid R.
Hemati, Sobhan
Abrégé
Compact whole slide image (WSI) representations can be learned using a suitably trained generative model. The generative model is trained on training data using an instance-based training. Using gradient sparsity and quantization losses, the generative model learns to generate compact (e.g., sparse and binary) representations and/or embeddings of whole slide images.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
26.
MACHINE-LEARNING FOR PROCESSING LEAD-INVARIANT ELECTROCARDIOGRAM INPUTS
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
A61B 5/349 - Détection de paramètres spécifiques du cycle de l'électrocardiogramme
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
UNIVERZITA KARLOVA (République tchèque)
Inventeur(s)
Schellenberg, Matthew J.
Roh, Jaroslav
Simunek, Tomas
Kubes, Jan
Karabanovich, Galina
Melnikova, Iuliia
Kerestes, Veronika
Sterba, Martin
Lencova, Olga
Kollarova, Petra
Abrégé
The present disclosure provides in one embodiment compounds of formula (I) that are DNA topoisomerase inhibitors useful in treating and/or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy, for example, with anthracycline drugs such as doxorubicin.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
C07D 277/60 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 261/20 - Composés hétérocycliques contenant des cycles oxazole-1, 2 ou oxazole-1, 2 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Abu Dayyeh, Barham K.
Abrégé
A system for bypassing a portion of a small intestine. The system includes an occlusion device and a bypass device. The occlusion device includes a tubular body, an occlusion member at a distal end portion of the tubular body, and an anchor member at a proximal end portion of the tubular body. The bypass device includes a liner, and an anchor member at a proximal end portion of the liner.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
High, Karin Westlund
Kunamneni, Adinarayana
Abrégé
A humanized anti-human P2X4R antibody, or an antigen binding fragment thereof, or a polypeptide, that inhibits human P2X4R activity, is provided as well as methods of making and using the antibody or an antigen binding fragment thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
Arizona Board of Regents on behalf of Arizona State University (USA)
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Berisha, Visar
Zhang, Jianwei
Schwedt, Todd J.
Chong, Catherine
Jayasuriya, Suren
Wu, Teresa
Abrégé
Described are platforms, systems, media, and methods for evaluating, monitoring, and/or treating a subject for brain injury based on machine learning analysis of one or more of brain imaging features, clinical features, demographic features, or speech features.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Asirvatham, Samuel J.
Abrégé
A wearable device combines its existing functions (e.g., a headphone) with non-invasive autonomic modulation using tragus or other external auditory meatus stimulation. The wearable device can output audio to a user, such as music, podcast, etc., and further provide modulation of the vagus nerve via tragus stimulation or other external auditory meatus stimulation to treat various diseases.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
32.
METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCERS
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
THE NETHERLANDS CANCER INSTITUTE / ANTONI VAN LEEUWENHOEK HOSPITAL (Pays‑Bas)
Inventeur(s)
Mansfield, Aaron S.
Kosari, Farhad
Baas, Paul
Abrégé
This document provides to methods and materials involved in assessing and/or treating a mammal (e.g., a human) having cancer (e.g., mesothelioma). For example, methods and materials provided herein can be used to identify a cancer (e.g., a mesothelioma) as being likely to respond to one or more immune checkpoint inhibitors. For example, methods and materials provided herein can be used to treat a mammal (e.g., a human) having cancer (e.g., mesothelioma) where the cancer treatment is selected based on whether or not the cancer is likely to be responsive to one or more immune checkpoint inhibitors.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Amoroso, Jillian
Abrégé
A wrap for collecting a plurality of lines, cords, tubes, or wires has been provided. In some implementations, the wrap may include a first surface and a second surface on opposite sides of the first layer, such that one may be viewed as being on the top of the first layer and the other on the bottom of the first layer when the wrap is in an unwrapped state. The first connection mechanism is removably attachable to the second connection mechanism to transition the wrap between the unwrapped state and a wrapped state. The first layer is configured to wrap around a plurality of lines, cords, tubes, or wires when the wrap is in a wrapped state, and a portion of the first layer overlaps another portion of the first layer when the wrap is in a wrapped state.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Kozicz, Laszlo Tamas
Pandey, Akhilesh
Morava-Kozicz, Eva
Kumar Garapati, Sri Ram Kishore
Budhraja, Rohit
Kim, Jinyong
Abrégé
This document provides methods and materials for assessing and/or treating mammals (e.g., humans) having a metabolic disorder (e.g., a congenital disorder of glycosylation (CDG)). For example, a circulating glycopeptide signature present in blood of a mammal (e.g., a human) having a CDG can be used to identify the mammal as having a phosphomannomutase 2 (PMM2)-CDG. This document also provides methods and materials for treating a mammal having a CDG (e.g., PMM2-CDG).
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Meves, Alexander
Abrégé
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having melanoma (e.g., primary cutaneous melanoma (PCM)). For example, methods and materials that can be used to determine whether or not a melanoma is likely to relapse (e.g., likely to relapse following treatment) are provided. For example, methods and materials for treating a mammal (e.g., a human) having melanoma where the treatment is selected based, at least in part, on whether or not the melanoma is likely to relapse are provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
36.
METHODS AND MATERIALS FOR MAKING RECOMBINANT VIRUSES
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Barry, Michael A.
Lu, Shao-Chia
Abrégé
This document provides methods and materials for making recombinant viruses. For example, recombination systems including (1) a viral vector (e.g., an adenoviral vector) having a genome comprising a nucleic acid sequence (e.g., an engineered DNA sequence) including a first recombinase site of a first recombinase (e.g., a FRT site), a packaging sequence, a recombinase site of a second recombinase (e.g., a loxP site), a second recombinase site of said first recombinase (e.g., a second FRT site), and a recombinase site of a third recombinase (e.g., an attP site); and (2) a donor nucleic acid including a first recombinase site of the second recombinase (e.g., a first loxP site), a multicloning site and/or nucleic acid that can encode a polypeptide of interest, a recombinase site of the third recombinase (e.g., an attB site), and a second recombinase site of the second recombinase (e.g., a second loxP site) are provided.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
37.
Systems and Methods for Lesion Depth Determination in Molecular Breast Imaging
Mayo Foundation for Medical Education and Research (USA)
CMR Naviscan (USA)
Inventeur(s)
O'Connor, Michael K.
Luo, Weidong
Abrégé
Systems and methods are provided for lesion depth determination in molecular breast imaging. The depth of a lesion in a breast of a subject may be determined during a molecular breast imaging (“MBI”) procedure where the resolving power of the detectors, such as gamma cameras, that degrades with distance from the face of the detector is exploited. By comparing the apparent size of a lesion in two opposing detectors, it is possible to estimate the distance of the lesion from each detector by modeling or measuring the resolution that changes with distance from the detectors. The systems and methods may be used during biopsy procedures to indicate the appropriate needle depth for biopsy of the lesion.
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
A61B 6/12 - Agencements pour détecter ou localiser des corps étrangers
A61B 6/42 - Agencements pour détecter des radiations spécialement adaptés au diagnostic par radiations
Arizona Board of Regents on behalf of Arizona State University (USA)
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Smetanick, Derek
Victor, Shaun
Tse, Ashley
Dalal, Dhrasti
Ramsey, Alan
Lott, David
Neubauer, Juergen
Muthuswamy, Jitendran
Abrégé
A neuromodulation device is provided that comprises a flexible layer comprising a non-conductive material, in which the layer is positioned in at least a partially tubular shape. The neuromodulation device comprises at least one cathodic band comprising at least one conductive cathodic contact housed by the layer. The neuromodulation device comprises an anodic band comprising at least one anodic contact housed by the layer. The neuromodulation device comprises is configured to receive a wireless signal to power and activate the at least one cathodic contact and the at least one anodic contact in a coordinated reset cycle.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/02 - ÉlectrothérapieCircuits à cet effet Parties constitutives
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Mcbride, Jeremy F.
Abrégé
Methods and materials are provided herein that can be used to separate healthy organs and/or tissues from organs and/or tissues to be subjected to, for example, heat or cold (e.g., during ablation procedures). Methods and materials also are provided herein that can be used to embolize blood vessels.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Wadei, Hani M.
Simcox, John
Hile, Chris
Loper, Jeffrey Cameron
Abrégé
This document provides devices, methods, and processes for an implantable urine flow sensor including a first end coupled to a first portion of a uretic stent, and a second end coupled to a second portion of the uretic stent. The implantable urine flow sensor is sized to fit within, and be operable within, an individual ureter.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Routman, David M.
Tryggestad, Erik J.
Moseley, Douglas J.
Brooks, Jamison L.
Abrégé
Knowledge-based quality assurance (QA) of organ-at-risk contours in radiotherapy planning assists with contour review based on features obtained from the contours. These contour-based features are input to one or more computational models to predict, determine, or otherwise identify erroneous contours in the radiotherapy plan. The computational models may include statistical models, distance metric-based models, and/or machine learning models.
G06V 10/75 - Organisation de procédés de l’appariement, p. ex. comparaisons simultanées ou séquentielles des caractéristiques d’images ou de vidéosApproches-approximative-fine, p. ex. approches multi-échellesAppariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexteSélection des dictionnaires
G06F 18/2433 - Perspective d'une seule classe, p. ex. une classification "une contre toutes"Détection de nouveautéDétection de valeurs aberrantes
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Wang, Shaopeng
Yu, Nanxi
Chen, Chao
Zhou, Xinyu
Castro, Januario E.
Moreno Cortes, Eider F.
Abrégé
Provided herein are methods of differentiating cell types in a cell population. The methods include removing at least some non-Chimeric Antigen Receptor (CAR)-T cells from a fluidic sample obtained from a subject without centrifuging the fluidic sample to produce a purified fluidic sample. The fluidic sample comprises CAR-T cells and the non-CAR-T cells. The methods also include capturing cells in the purified fluidic sample on a surface that comprises binding moieties that bind at least to the CAR-T cells to produce a captured cell population. In addition, the methods also include distinguishing the CAR-T cells from the non-CAR-T cells in the captured cell population using a trained machine learning model to produce a captured CAR-T cell population data set. Additional methods as well as related devices and systems are also provided.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G06V 10/70 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique
43.
CONTINUOUS THREE-DIMENSIONAL IMAGING FOR MAGNETIC RESONANCE ELASTOGRAPHY
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Forghanian-Arani, Arvin
Trzasko, Joshua D.
Sui, Yi
Araoz, Philip A.
Ehman, Richard L.
Huston, Iii, John
Abrégé
Described here are systems and methods for a robust magnetic resonance elastography (“MRE”) imaging platform for rapid dynamic 3D MRE imaging. The imaging platform includes an MRE pulse sequence and advanced image reconstruction framework that work synergistically in order to greatly expand the domains where MRE can be deployed successfully.
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Savastano, Luis E.
Liu, Yang
Abrégé
Disclosed herein are systems, devices, and methods for accessing a subdural space. In some embodiments, an apparatus may comprise a shaft configured to be slidably disposed within a lumen of a catheter. The shaft may be configured to be advanced distally from a distal end of the catheter and into a blood vessel of a subject. The shaft may include a perforating tip including an energy element configured to generate radiofrequency energy to form an opening through a wall of the blood vessel and dura of the subject and into an extravascular space of the subject. A curved section may be configured to be radially constrained within the lumen of the catheter and to curve toward the wall of the blood vessel and the dura upon exiting the lumen of the catheter such that the energy element is positioned to form the opening.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Hsieh, Scott S.
Abrégé
A method for acquiring x-ray data from a subject and generating a computed tomography (CT) image of the subject includes receiving a set of illumination field data including an illumination field produced by each of a plurality of focal spot positions of an x-ray source, selecting at least one sequence of at least two illumination fields based on at least one subject-specific parameter, assigning an illumination field from the selected at least one sequence to each gantry rotation angle in a plurality of gantry rotation angles, acquiring x-ray data from a subject for each gantry rotation angle using a focal spot position associated with the illumination field that is assigned to the gantry rotation angle, and generating an image slice based on the acquired x-ray data for each of the plurality of gantry rotation angles. The x-ray data can include a number of photons received by the detector array.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G21K 1/02 - Dispositions pour manipuler des particules ou des rayonnements ionisants, p. ex. pour focaliser ou pour modérer utilisant des diaphragmes, des collimateurs
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Barnes, Darryl E.
Smith, Jay
Abrégé
Some embodiments provide a soft tissue device, such as a transverse carpal ligament cutting device having one or more balloons that are deflated when the device is in an inactive position and are inflated when the device is in an active position. Other embodiments provide a soft tissue cutting method, such as a method of cutting a transverse carpal ligament that uses a soft tissue cutting device.
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Barnes, Darryl E.
Smith, Jay
Abrégé
The invention provides a tissue cutting device comprising a handle, a first blade. and a second blade. The second blade is coupled to the handle. The second blade is rotatable relative to the first blade such that the second blade is configured to rotate between a first position and a second position. The second blade is in a same plane as the first blade when the second blade is in the first position. The second blade is rotated into a different plane from the first blade when the second blade is rotated from the first position toward the second position.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Allawi, Hatim T.
Kaiser, Michael W.
Lidgard, Graham P.
Taylor, William R.
Sander, Tamara J.
Vaccaro, Abram M.
Abrégé
Provided herein is technology for neoplasia screening, and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of cancer, in particular, colorectal cancer.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/6853 - Réactions d’amplification d’acides nucléiques utilisant des amorces ou des matrices modifiées
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G16Z 99/00 - Matière non prévue dans les autres groupes principaux de la présente sous-classe
49.
ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A
Mayo Foundation for Medical Education and Research (USA)
University of Florida Research Foundation, Inc. (USA)
Inventeur(s)
Burnett, Jr., John C.
Sangaralingham, Sasantha J.
Malany, Siobhan
Peddibhotla, Satyamaheshwar
Abrégé
In some embodiments, the present disclosure provides a compound(S) or (R)-N-(4.6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide, as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound, and methods of treating. e.g., metabolic diseases using the compound are also provided.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
FIOS THERAPEUTICS LLC (USA)
Inventeur(s)
Russell, Stephen J.
Krotova, Karina
Mcgregor, Christopher G.A.
Abrégé
Provided herein are genetically modified ungulate cells expressing a chimeric antigen receptor. Also provided herein are transgenic ungulate cells that can be used as cell carriers for the delivery of oncolytic viruses in cancer therapy. Also provided are transgenic ungulates comprising these cells, methods of making these cells, and methods of treating cancer by administering these cells to a subject in need thereof. Also provided are transgenic ungulate cells that express a chimeric antigen receptor and uses thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Pandey, Mukesh K.
Lowe, Val J.
Bansal, Aditya
Stein, Heather M.
Gundam, Surendra Reddy
Abrégé
Disclosed are compounds of formula (1), formula (2), formula (75), formula (80) and formula (90): wherein R1, R2, R3, R4, and R5 can be selected from the group consisting of hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted haloalkyl, substituted haloalkyl, unsubstituted hydroxyalkyl, substituted hydroxyalkyl, benzyl, phenyl, substituted phenyl, unsubstituted alkenyl, substituted alkenyl, unsubstituted cycloalkyl, substituted cycloalkyl, hydroxy, unsubstituted alkoxy, substituted alkoxy, unsubstituted haloalkoxy, substituted haloalkoxy, unsubstituted phenoxy, substituted phenoxy, unsubstituted sulfonyloxy, substituted sulfonyloxy, carbonyl, carboxy, unsubstituted amino, substituted amino, unsubstituted amido, and substituted amido, and wherein at least one atom in R1 is replaced with a positron emitter. Also disclosed are methods for in vivo imaging of a subject using the compound of formula (1) or formula (2) or formula (75) or formula (80) or formula (90).
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Behfar, Atta
Occhino, John A.
Trabuco, Emanuel C.
Abrégé
A method for treating exposure of surgical mesh in a subject generally includes administering PEP to tissue adjacent to an area of exposed surgical mesh in an amount effective to treat the area of exposed surgical mesh. In another aspect, a method for treating exposure of surgical mesh in a subject generally includes surgically closing an area of exposed surgical mesh and administering PEP to epithelium adjacent to the surgical closure in an amount effective to treat the area of exposed surgical mesh. In one or more embodiments of either aspect, the amount effective to treat the area of exposed surgical mesh can be an amount effective to increase proliferation of epithelium to decrease the area of exposed surgical mesh, increase thickness of epithelium covering the surgical mesh, or increase vascularization of epithelium covering the surgical mesh.
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
53.
Use of Resected Liver Serum for Whole Liver-Engineering
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Ross, Jeffrey
Young, Anne
Haarstad, Allie
Nyberg, Scott
Abrégé
The disclosure provides a method of using blood or fractions thereof, e.g., serum, obtained from a mammal subjected to liver surgery, for example, obtained following a partial hepatectomy, to increase the engraftment, proliferation and/or functionality of cells on a biocompatible scaffold.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Barry, Michael A.
Abrégé
This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Dietz, Allan B.
Gustafson, Michael P.
Abrégé
This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4+ lymphocytes, CD8+ lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14+HLA-DRlo/neg monocytes, and/or CD86+ monocytes per unit volume (e.g., cells per μL or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Shapiro, Virginia M.
Medina, Kay L.
Abrégé
This document relates to methods and materials for treating myeloid disorders in a mammal (e.g., a human). For example, methods and materials for using one or more inhibitors of early lymphopoiesis to treat a mammal having a myeloid disorder (e.g., a SF3B1-associated myeloid disorder) are provided.
57.
COMPOSITIONS AND METHODS FOR REPAIRING DAMAGE TO SKELETAL MUSCLE
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Behfar, Atta
Trabuco, Emanuel C.
Abrégé
A method of treating injured skeletal muscle tissue generally includes applying to injured skeletal muscle tissue a therapeutic composition that includes a purified exosome product (PEP) and a pharmaceutically acceptable carrier. In one or more embodiments, the method includes applying from 1×1011 PEP exosomes to 1×1013 PEP exosomes to the injured skeletal muscle. In one or more embodiments, the therapeutic composition further includes a supportive matrix such as a collagen scaffold, a tissue sealant, fibrin glue, or a hydrogel.
Mayo Foundation for Medical Education and Research (USA)
Arizona Board of Regents on behalf of Arizona State University (USA)
Inventeur(s)
Grys, Thomas E.
Lake, Douglas F.
Grill, Francisca J.
Abrégé
This document provides methods and materials involved in detecting and/or treating coccidioidomycosis (e.g., valley fever). For example, methods and materials for using a rapid antibody lateral flow assay to detect anti-CTS1 antibodies are provided. Methods and materials for treating coccidioidomycosis (e.g., valley fever) in a mammal (e.g., a human) identified as having anti-CTS1 antibodies via a lateral flow assay also are provided.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
59.
USING AUTOLOGOUS MESENCHYMAL STEM CELLS TO TREAT MULTIPLE SYSTEM ATROPHY
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Singer, Wolfgang
Low, Phillip
Abrégé
This document provides methods and materials for treating multiple system atrophy. For example, methods and materials for using autologous mesenchymal stem cells (e.g., adipose derived mesenchymal stem cells) to treat multiple system atrophy are provided.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Yalamuri, Suraj M.
Behfar, Atta
Rosenbaum, Andrew N.
Abrégé
Cannula devices can be used for withdrawing venous blood from a patient and returning arterial blood to the patient after extracorporeal oxygenation. For example, this document describes dual lumen cannula devices and methods for their use with systems such as extracorporeal membrane oxygenation (ECMO) systems. The technology described herein includes a cannula device, and a methodology utilizing the cannula device, to provide complete hemodynamic support incorporating both venous drainage cannula and arterial return cannula in a single cannula device.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Vile, Richard G.
Diaz Marcano, Rosa M.
Kottke, Timothy J.
Tonne, Jason M.
Abrégé
This document relates to methods and materials involved in treating cancer. For example, methods and materials for using (a) APCs (e.g., dendritic cells) designed to release a viral vector that can infect a T cell (e.g., an infectious retroviral vector or an infectious lentiviral vector) and drive expression of an antigen receptor (e.g., a CAR) within that T cell and (b) an antigenic composition containing one or more antigens that can be presented to T cells within the mammal by APCs of the administered population and/or by other APCs within the mammal to produce dual specific CAR+ memory T cells are provided.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Behfar, Atta
Houdek, Matthew T.
Abrégé
A composition includes a purified exosome product (PEP) and a pharmaceutically acceptable carrier that includes a supportive matrix. The supportive matrix can include a collagen scaffold, a tissue sealant, or a fibrin sealant. A method of repairing damaged tendon tissue generally includes applying a composition that includes PEP and a pharmaceutically acceptable carrier to damaged tendon tissue. In one or more embodiments, the composition applied to the damaged tendon tissue includes a supportive matrix.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Behfar, Atta
Zhao, Chunfeng D.
Abrégé
A method of repairing a damaged bone-tendon interface in a subject generally includes contacting the damaged bone-tendon interface with an effective amount of a composition that includes purified exosome product (PEP) and a pharmaceutically acceptable carrier. In one or more embodiments, the damaged bone-tendon interface includes complete separation of tendon from bone and the method further includes surgically reattaching the tendon to the bone. In one or more embodiments, the damaged tendon-bone interface comprises partial separation of tendon from bone and the method includes implanting the PEP composition at a site effective for contacting the PEP composition with the damaged tendon-bone interface.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Attia, Itzhak Zachi
Friedman, Paul A.
Lopez-Jimenez, Francisco
Kapa, Suraj
Abrégé
Systems, methods, devices, and techniques for estimating a heart disease prediction of a mammal. An electrocardiogram (ECG) procedure is performed on a mammal, and a computer system obtains ECG data that describes results of the ECG over a period of time. The system provides a predictive input that is based on the ECG data to a predictive model, such as a neural network or other machine-learning model. In response, the predictive model processes the input to generate an estimated heart disease predictive characteristic of the mammal. The system outputs the estimated heart disease prediction of the mammal for presentation to a user.
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Mukhopadhyay, Debabrata
Bhattacharya, Santanu
Pal, Krishnendu
Rachamala, Hari K.
Kulkarni, Tanmay A.
Dutta, Shamit K.
Wang, Enfeng
Abrégé
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having a cancer (e.g., a pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), or a breast cancer). For example, methods and materials that can be used for assessing if a cancer (e.g., a pancreatic cancer, such as PDAC, or a breast cancer) is likely to be successfully treated are provided. This document also provides methods and materials for treating a mammal (e.g., a human) having a cancer (e.g., a pancreatic cancer, such as PDAC, or a breast cancer).
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Copland, Iii, John A.
Mody, Kabir
Gleba, Justyna J.
Patel, Tushar C.
Abrégé
This document provides methods and materials for treating cancer (e.g., liver cancer such as hepatocellular carcinoma (HCC)) using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors (e.g., a selective SCD1 inhibitor (SSI)) and one or more tyrosine kinase inhibitors.
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Gonzalez Suarez, Alan M.
Revzin, Alexander
Abrégé
This document provides methods, devices, and systems for detecting the presence, absence, or amount of two or more analytes present within a small volume (e.g., less than 10 μL) of a sample (e.g., a blood sample) obtained from a mammal (e.g., a human such as a human neonate). For example, methods and materials for using plasma separation and multiplex analyte detection to detect two or more analytes (e.g., proteins, carbohydrates, lipids, nucleic acids, intact cells, intact viruses, intact microorganisms, and/or chemicals) within a small volume of a blood sample are provided.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/66 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les sucres du sang, p. ex. le galactose
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Copland Iii, John A.
Cai, Hancheng
Parent, Ephraim E.
Li, Kang-Po
Abrégé
The present disclosure provides SCD1-targeted radiotracers useful as diagnostic tools for diseases, disorders, and conditions where overexpression of SCD1 is implicated in pathology. Pharmaceutical compositions comprising said radiotracers and methods of using the radiotracers for imaging organs and/or tissues affected with SCD1-associated disorder are also provided. Suitable examples of SCD1-associated disorders include cancer, skin disorders, metabolic disorders, inflammatory disorders, and neurodegenerative disorders.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Dubey, Divyanshu
Pittock, Sean J.
Mills, John R.
Dasari, Surendra
Knight, Andrew M.
Rezk, Mohamed
Abrégé
This document provides methods and materials for assessing and/or treating mammals having a paraneoplastic neurologic syndrome (PNS). For example, methods and materials for using a Sloan Kettering virus family transcriptional corepressor 2 (SKOR2) polypeptide and/or one or more fragments of a SKOR2 polypeptide to detect the presence or absence of autoantibodies present in immune-mediated PNS are provided.
70.
COGNITIVE FUNCTION IMPROVEMENTS AND BIOMARKER-MODULATED DEEP BRAIN STIMULATION
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Kucewicz, Michal T.
Worrell, Gregory A.
Kremen, Vaclav
Marks, Victoria S.
Lech, Michal
Abrégé
Verbal memory impairment is a common symptom of temporal lobe epilepsy (“TLE”). The ability to encode and recall verbal memories can be probed with the classic free recall task. This study had three overarching hypotheses: 1) increased seizure frequency will lead to decreased verbal memory, 2) stimulation will modulate memory performance, and 3) stimulation will modulate the underlying neural correlates of memory. The study investigated these hypotheses in patients receiving chronic DBS to bilateral ANT. Recordings were obtained from individuals with drug resistant mesial TLE implanted with an investigational MEDTRONIC SUMMIT RC+S™ sensing and stimulation device. As patient seizure diaries are notoriously inaccurate, the patient's continuous local field potential (“cLFP”) was scored for seizures using a validated seizure classifier with trained epileptologist review, resulting in a reliable seizure diary. The subjects completed free recall memory tasks in their home environment with cLFP and behavioral data streamed to a handheld device and cloud repository.
Verbal memory impairment is a common symptom of temporal lobe epilepsy (“TLE”). The ability to encode and recall verbal memories can be probed with the classic free recall task. This study had three overarching hypotheses: 1) increased seizure frequency will lead to decreased verbal memory, 2) stimulation will modulate memory performance, and 3) stimulation will modulate the underlying neural correlates of memory. The study investigated these hypotheses in patients receiving chronic DBS to bilateral ANT. Recordings were obtained from individuals with drug resistant mesial TLE implanted with an investigational MEDTRONIC SUMMIT RC+S™ sensing and stimulation device. As patient seizure diaries are notoriously inaccurate, the patient's continuous local field potential (“cLFP”) was scored for seizures using a validated seizure classifier with trained epileptologist review, resulting in a reliable seizure diary. The subjects completed free recall memory tasks in their home environment with cLFP and behavioral data streamed to a handheld device and cloud repository.
Through implementation of generalized linear mixed models (GLMM), the study was able to determine that ANT stimulation modulates memory performance, but changes in the seizure rate were not predictive of changes in memory performance. Analyzing the continuous local field potential recordings from these tasks, the study found that spectral power in the theta frequency band in the left ANT and hippocampus correlated with acute memory performance and chronic therapeutic stimulation frequency received.
Verbal memory impairment is a common symptom of temporal lobe epilepsy (“TLE”). The ability to encode and recall verbal memories can be probed with the classic free recall task. This study had three overarching hypotheses: 1) increased seizure frequency will lead to decreased verbal memory, 2) stimulation will modulate memory performance, and 3) stimulation will modulate the underlying neural correlates of memory. The study investigated these hypotheses in patients receiving chronic DBS to bilateral ANT. Recordings were obtained from individuals with drug resistant mesial TLE implanted with an investigational MEDTRONIC SUMMIT RC+S™ sensing and stimulation device. As patient seizure diaries are notoriously inaccurate, the patient's continuous local field potential (“cLFP”) was scored for seizures using a validated seizure classifier with trained epileptologist review, resulting in a reliable seizure diary. The subjects completed free recall memory tasks in their home environment with cLFP and behavioral data streamed to a handheld device and cloud repository.
Through implementation of generalized linear mixed models (GLMM), the study was able to determine that ANT stimulation modulates memory performance, but changes in the seizure rate were not predictive of changes in memory performance. Analyzing the continuous local field potential recordings from these tasks, the study found that spectral power in the theta frequency band in the left ANT and hippocampus correlated with acute memory performance and chronic therapeutic stimulation frequency received.
Not all patients are candidates for devices with chronic sensing capabilities, and this study indicates that changes in verbal memory performance can provide a suitable metric of therapy effectiveness in lieu of a reliable, objective seizure diary. But for those who do receive these and similar devices, thalamic-hippocampal spectral activities can be used to track and predict memory performance acutely and chronically, as well as predict the effect of therapeutic deep brain stimulation. Our study demonstrates chronic improvement of verbal memory with a new biomarker-based technology for remote task administration and modulation of the associated neural activities.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
71.
MODULATION OF EXTRACELLULAR VESICLES WITH ELECTRICAL STIMULATION
Mayo Foundation for Medical Education and Research (USA)
Regents of the University of Minnesota (USA)
Inventeur(s)
Wang, Hai-Long
Worrell, Gregory A.
Lennon, Vanda A.
Dong, Haidong
Bemis, Lynne T.
Melvin, Richard G.
Abrégé
Methods for modulating the release and content of extracellular vesicles from target cells using electrical stimulation are provided. Compositions comprising extracellular vesicles or extracts of extracellular vesicles and methods of administering the compositions to a subject are also provided.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Taylor, William R.
Harrington, Jonathan J.
Quint, Patrick S.
Zou, Hongzhi
Bergen, Iii, Harold R.
Smith, David I.
Ahlquist, David A.
Abrégé
This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
C12Q 1/40 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase une amylase
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
73.
ENDOSCOPIC OR ENDOBRONCHIAL TUMOR TREATMENT SYSTEMS AND METHODS
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Abu Dayyeh, Barham K.
Tri, Jason A.
Asirvatham, Samuel J.
Kapa, Suraj
Kern, Ryan M.
Mullon, John J.
Abrégé
Systems and methods can be used endoscopically to treat tumors in mediastinal, abdominal, and peri-rectal spaces. For example, this document describes systems and methods for endoscopic delivery of non-thermal pulsed electrical field or electroporation to such tumors. In addition, the systems and methods prime the immune system by re-introducing obtained and processed tissue or aspirates back to the local tumor environment after ex-vivo denaturing and emulsification of the tumor tissue or other immune enhancing substances such a monoclonal or multifunctional antibodies. The re-introduction of the processed tumor cells or immune enhancing substances will create an antigenic primed environment to the enhanced immune response generated by the pulsed electrical field. This will harness the power of the immune system as an ablative modality to the local tumor while systemically targeting metastatic disease.
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61B 10/04 - Instruments endoscopiques, p. ex. instruments de type cathéther
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Dasari, Surendra
Shah, Mithun V.
Chen, Dong
Abrégé
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having multiple myeloma (MM). For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) having MM is likely to develop one or more therapy-related myeloid neoplasms (t-MNs) are provided. This document also relates to methods and materials for treating a mammal (e.g., a human) having MM where the treatment is selected based, at least in part, on whether or not the mammal is likely to develop one or more t-MNs.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/255 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides oxygénés du soufre ou de leurs thio-analogues
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Dearani, Joseph A.
Walji, Salim M.
Abrégé
The present disclosure relates to a protective garment. The garment includes a body shaped for wear on a body part and a pocket assembly coupled to the body. The pocket assembly includes a first pocket comprising a wall and a pouch at least partially defined by the wall, a second pocket adjacent to the first pocket, the second pocket defining a second pouch separate from the first pouch, and an opening extending through the wall of the first pocket.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Schafer, Marissa J.
Lebrasseur, Nathan K.
Haak, Andrew J.
Carver, Chase M.
Abrégé
This document relates to methods and materials for using and/or assessing one or more senotherapeutic agents. For example, methods and materials for determining the efficacy of an anti-senescence treatment in a mammal (e.g., a human) as well as methods and materials for effectively treating a mammal with an anti-senescence treatment are provided.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
77.
ISOTYPING IMMUNOGLOBULINS USING ACCURATE MOLECULAR MASS
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Chen, Shigao
Gong, Ping
Lok, U Wai Francisco
Trzasko, Joshua D.
Abrégé
Systems and methods are provided to adaptively suppress reverberation clutter signals in ultrasound imaging. A robust principal component analysis (RPCA) may be used to separate a static or low dimension background signal from sparse, moving or high dimension objects in the presence of outliers. A tissue signal may be transformed to the wavelet domain to fulfill the sparsity conditions of RPCA. The use of the RPCA combined with wavelet kernels may be used to suppress reverberation clutter signals to achieve robust ultrasound attenuation coefficient estimation.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Puffer, Ross C.
Parney, Ian F.
Abrégé
This document provides methods and materials involved in identifying mammals as having, or being likely to have, a traumatic brain injury (TBI). This document also provides methods for treating mammals identified as having, or being likely to have, a TBI, based on the identification methods described herein.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
80.
METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Parney, Ian F.
Abrégé
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having brain cancer (e.g., glioblastoma (GBM)). For example, the presence of a population of CD9+extracellular vesicles (EVs; e.g., CD9+ plasma EVs) having a distinct profile in a sample (e.g., a blood sample) obtained from a mammal (e.g., a human) can be used to identify that mammal as having brain cancer (e.g., GBM). Also provided are materials and methods for treating mammals (e.g., a human) having brain cancer (e.g., GBM)
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Chaib, Andy Selim
Kirkland, James L.
Tchkonia, Tamar
Lanza, Ian R.
Jensen, Michael D.
Abrégé
Methods and materials for identifying and treating senescence and senescence-related and/or age-related diseases are provided herein. For example, this document provides methods and materials for using secreted PD-L2 to identify senescence/age-related diseases, as well as methods for using secreted PD-L2 as a therapeutic target for senescence/age-related diseases.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Behfar, Atta
Terzic, Andre
Abrégé
A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
83.
USE OF GASTRIC EMPTYING TO PREDICT AND MANAGE GLYCEMIA IN DIABETES MELLITUS
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Bharucha, Adil E.
Kudva, Yogish C.
Manduca, Armando
Abrégé
This document describes systems and methods for managing glycemia in patients with diabetes mellitus by optimizing insulin delivery dosages and timing. For example, this document describes systems and methods that utilize a patient's gastric emptying rate and other parameters to determine the optimal insulin delivery dosages and timing for the patient.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Freeman, William D.
Erickson, Bradley J.
Abrégé
Subarachnoid hemorrhage (SAH) is detected using a suitably trained machine learning model. The machine learning model may take medical images as an input. Additionally or alternatively, the machine learning model may take quantified SAH blood volume (qvSAH) data and patient health data as an input. In some examples, the machine learning model may generate classified feature data indicating a risk stratification, severity of illness, and/or prognosis. A report may be generated, which may include suggestions for clinical decision support, interventions based on the severity of illness, or triaging for the patient.
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G06N 20/20 - Techniques d’ensemble en apprentissage automatique
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
85.
System and Method for Classifying Autosomal Dominant Polycystic Kidney Disease Patients
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventeur(s)
Irazabal Mira, Maria V.
Torres, Vicente E.
Harris, Peter C.
Rangel Latuche, Laureano J.
Abrégé
An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.
A61B 5/107 - Mesure de dimensions corporelles, p. ex. la taille du corps entier ou de parties de celui-ci
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
86.
Systems and Methods for Multi-Kernel Synthesis and Kernel Conversion in Medical Imaging
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Yu, Lifeng
Missert, Andrew D.
Leng, Shuai
Mccollough, Cynthia H.
Fletcher, Joel G.
Abrégé
Systems and methods are provided for synthesizing information from multiple image series of different kernels into a single image series, and also for converting a single baseline image series of a kernel reconstructed by a CT scanner to image series of various other kernels, using deep-learning based methods. For multi-kernel synthesis, a single set of images with desired high spatial resolution and low image noise can be synthesized from multiple image series of different kernels. The synthesized kernel is sufficient for a wide variety of clinical tasks, even in circumstances that would otherwise require many separate image sets. Kernel conversion may be configured to generate images with arbitrary reconstruction kernels from a single baseline kernel. This would reduce the burden on the CT scanner and the archival system, and greatly simplify the clinical workflow.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G06F 18/21 - Conception ou mise en place de systèmes ou de techniquesExtraction de caractéristiques dans l'espace des caractéristiquesSéparation aveugle de sources
G06F 18/214 - Génération de motifs d'entraînementProcédés de Bootstrapping, p. ex. ”bagging” ou ”boosting”
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
87.
BIDIRECTIONAL SPIKE-TIMING-DEPENDENT BRAIN NETWORK GAIN CONTROL
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Asp, Anders J.
Lujan, Jose L.
Abrégé
In an example method for increasing synaptic gain in a region of a brain of a subject, a first electromagnetic pulse is applied to a first neural element of a first neuron of the subject using a first electrode. The first neural element includes a first synapse coupled to a second neuron of the subject. Subsequent to applying the first electromagnetic pulse to the first neural element, a second electromagnetic pulse is applied to a second neural element of the second neuron using a second electrode.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
88.
SYSTEMS AND METHODS FOR QUANTIFYING MULTISCALE COMPETITIVE LANDSCAPES OF CLONAL DIVERSITY IN GLIOBLASTOMA
Mayo Foundation for Medical Education and Research (USA)
Arizona Board of Regents on Behalf of Arizona State University (USA)
Inventeur(s)
Hu, Leland S.
Swanson, Kristin R.
Mitchell, J. Ross
Tran, Nhan L.
Li, Jing
Wu, Teresa
Abrégé
Methods that implement image-guided tissue analysis, MRI-based computational modeling, and imaging informatics to analyze the diversity and dynamics of molecularly-distinct subpopulations and the evolving competitive landscapes in human glioblastoma multiforme (“GBM”) are provided. Machine learning models are constructed based on multiparametric MRI data and molecular data (e.g., CNV, exome, gene expression). Models can also be built based on specific biological factors, such as sex and age. Inputting MRI data into the trained predictive models generates maps that depict spatial patterns of molecular markers, which can be used to quantify and co-localize regions molecularly distinct subpopulations in tumors and other regions, such as the non-enhancing parenchyma, or brain around tumor (“BAT”) regions.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Van Deursen, Jan M.A.
Li, Hu
Sturmlechner, Ines
David, Nathaniel Eames
Abrégé
This document provides methods and materials involved in promoting immune surveillance against cancer cells. For example, methods and materials administering one or more chemokine (C-X-C motif) ligand 14 (CXCL 14) polypeptides (and/or nucleic acids designed to encode a CXCL 14 polypeptide) to cancer cells within a mammal (e.g., a human) having cancer to promote immune surveillance against the cancer cells are provided.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Kenderian, Saad J.
Roman, Claudia Manriquez
Cox, Michelle J.
Sakemura, Reona
Abrégé
This document provides methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor T cells having reduced expression levels of a tumor necrosis factor receptor 2 (TNFR2) polypeptide in an adoptive cell therapy (e.g., a chimeric antigen receptor (CAR) T cell therapy) to treat a mammal (e.g., a human) having cancer are provided.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Pathangey, Latha B.
Cohen, Peter A.
Gendler, Sandra J.
Vardam-Kaur, Trupti
Abrégé
This document relates to methods and materials related to isolated polypeptides, polypeptide preparations, and methods for using one or more isolated polypeptides to activate T cells. For example, polypeptides that can be used to activate T cells to generate antigen-specific T cells are provided. In some cases, T cells activated as described herein can be administered to a mammal having cancer (e.g., MM) or a precancerous condition (e.g., MGUS) to treat the mammal (e.g., to induce an immune response against the cancer or the precancerous condition).
Mayo Foundation for Medical Education and Research (USA)
Regents of the University of Minnesota (USA)
Inventeur(s)
Friedman, Paul A.
Attia, Itzhak Zachi
Lerman, Gilad
Abrégé
In some aspects, values of features obtained from training first and second machine-learning models are analyzed to correlate at least a subset of features from the first machine-learning model with at least a subset of features from the second machine-learning model. The correlated features are then applied to update the first or second machine-learning model, or to train a third machine-learning model. In other aspects, a generator machine-learning model processes a seed and a target characteristic indicator to generate a synthetic ECG signal. The synthetic ECG signal is biased according to a target physiological characteristic represented by the target characteristic indicator. The generator machine-learning model can be trained using an expert machine-learning model and in an adversarial process with a discriminator machine-learning model.
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Attia, Itzhak Zachi
Friedman, Paul A.
Asirvatham, Samuel J.
Noseworthy, Peter A.
Kapa, Suraj
Lopez-Jimenez, Francisco
Abrégé
Apparatuses and methods are provided to predict or diagnose an ischemic event, such as a stroke or a transient ischemic attack (TIA). A machine-learning model such as a neural network is generated that allows for recognition of an ECG consistent with an ischemic event. A system is trained and used to process a recording of ECG data from a patient to generate a prediction indicating a likelihood that the patient will experience a stroke. In other examples, a system is trained and used to process a recording of ECG data from a patient and detect an ischemic event for the patient who did not appear to have such an ischemic event.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
VYRIAD, INC. (USA)
Inventeur(s)
Schulze, Autumn, J.
Russell, Stephen, J.
Boyd, Kyla, A.
Muñoz Alía, Miguel, A.
Russell, Luke
Abrégé
e.g.e.g., a human) having cancer (e.g., cancers that exhibit little or no response to treatment with an oncolytic virus (or nucleic acid coding for an oncolytic virus) alone) are provided.
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Badley, Andrew D.
Nguyen, Amy M.
Kaufmann, Iv, Scott H.
Pang, Yuan-Ping
Dai, Haiming
Abrégé
This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/21 - Esters, p. ex. nitroglycérine, sélénocyanates
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
Mayo Foundation for Medical Education and Research (USA)
The Government of The United States, as Represented by the Secretary of the Army (USA)
Inventeur(s)
Techentin, Robert W.
Curry, Timothy B.
Joyner, Michael J.
Holmes, Iii, David R.
Haider, Clifton R.
Felton, Christopher L.
Gilbert, Barry K.
Van Dorn, Charlotte Sue
Carey, William A.
Convertino, Victor A.
Abrégé
In accordance with some embodiments, systems, methods, and media for estimating compensatory reserve and predicting hemodynamic decompensation using physiological data are provided. In some embodiments, a system for estimating compensatory reserve is provided, the system comprising: a processor programmed to: receive a blood pressure waveform of a subject; generate a first sample of the blood pressure waveform with a first duration; provide the sample as input to a trained CNN that was trained using samples of the first duration from blood pressure waveforms recorded from subjects while decreasing the subject's central blood volume, each sample being associated with a compensatory reserve metric; receive, from the trained CNN, a first compensatory reserve metric based on the first sample; and cause information indicative of remaining compensatory reserve to be presented.
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
G06N 3/004 - Vie artificielle, c.-à-d. agencements informatiques simulant la vie
G06N 3/008 - Vie artificielle, c.-à-d. agencements informatiques simulant la vie fondés sur des entités physiques commandées par une intelligence simulée de manière à reproduire des formes de vie intelligentes, p. ex. fondés sur des robots reproduisant les animaux ou les humains dans leur apparence ou leur comportement
99.
Systems and Methods for Correcting and Optimizing a Visual Field
Mayo Foundation for Medical Education and Research (USA)
Inventeur(s)
Khanna, Cheryl L.
Iezzi, Raymond
Matsumoto, Jane M.
Abrégé
Described herein is a system and method for correcting a visual field of a subject using a predicted visual field that includes visual field defects from facial contours of the subject. In an embodiment. the predicted visual field may be determined using a three-dimensional (3D) reconstruction of the face of the subject which may be generated from a two-dimensional (2D) image of the subject using a convolution neural network. A system and method for optimizing a head turn angle of a subject for determining a visual field of a subject is also described herein. An optimal head turn angle may be determined using the 3D reconstruction of the face of the subject. In some embodiments, after the visual field is maximized with positioning of the head. residual facial contour induced defects can be predicted and a final corrected field can be generated.
A61B 3/024 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour la détermination du champ de vision, p. ex. périmètres
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
Mayo Foundation for Medical Education and Research (USA)
Sanford Burnham Prebys Medical Discovery Institute (USA)
Inventeur(s)
Bram, Richard J.
Pinkerton, Anthony B.
Serguienko, Eduard
Abrégé
The present application provides, inter alia, a compound of Formula (I):
The present application provides, inter alia, a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, and R6 are as described herein. Methods of making these compounds and methods of using these compound for treating diseases such as cancer are also provided.
C07D 251/66 - Dérivés de la mélamine dans lesquels un hétéro-atome est lié directement à un atome d'azote de la mélamine
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles